Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shield TherapeuticsFRA:1JS +0.74% Equity-to-Asset is -0.23 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Shield Therapeutics ranks worse than 93.74% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shield Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €-12.88 Mil. Shield Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was €55.69 Mil.
Therefore, Shield Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -0.23.
The historical rank and industry rank for Shield Therapeutics's Equity-to-Asset or its related term are showing as below:
FRA:1JS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23 Med: 0.9 Max: 0.93
Current: -0.23
During the past 12 years, the highest Equity to Asset Ratio of Shield Therapeutics was 0.93. The lowest was -0.23. And the median was 0.90.
FRA:1JS's Equity-to-Asset is ranked worse than 93.74% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs FRA:1JS: -0.23
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Shield Therapeutics Equity-to-Asset Related Terms
Shield Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1JS vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Shield Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (FRA:1JS) has a Equity-to-Asset of -0.23 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #943 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 93.7%.
Is Shield Therapeutics' Equity-to-Asset too high?
Shield Therapeutics' current Equity-to-Asset is -0.23. Based on the distribution chart, Shield Therapeutics ranks #943 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #943 out of 1006 companies for Equity-to-Asset. This places Shield Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Equity-to-Asset is -0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 31.5% below its estimated fair value. The current Equity-to-Asset is -0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Equity-to-Asset is -0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JS has been successfully added to your 
